Mounjaro tirzepatide APPROVED
Drug Profile
ModalityPeptide
RouteSC
Therapy AreaCVRM
Launch2022-05-13
US LOE2036-05-01
Peak Sales Est$25000M
Formulations[{"id":"mounjaro-sc","doses":"2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg","route":"SC","device":"Pre-fill
Companies
LLY (ORIGINATOR)100%
Mechanism: GLP-1/GIP dual agonist
Expert: Dual agonist of GLP-1 and GIP receptors, providing synergistic effects on glucose homeostasis, appetite suppression, and weight loss through central and peripheral mechanisms.
Everyday: Mimics two gut hormones that regulate appetite and blood sugar. Helps people feel full and improves how the body processes sugar.
Targets: ["GLP-1","GIP"]
Revenue History
PeriodRevenue ($M)
Q3 2024$3,100M
2024$11,500M
2023$5,200M
Programs (1)
IndicationStageKey StudyRegional Status
T2DAPPROVEDSURPASS[{"stage":"APPROVED","region":"US","approval_date":"2022-05-13"},{"stage":"APPRO
Notes
Tirzepatide, a dual GLP-1 and GIP receptor agonist for type 2 diabetes. First-in-class dual incretin agonist; demonstrated superior glycemic control and weight loss vs GLP-1 agonists alone; weekly SC injection.
Data from Supabase · Updated 2026-03-24